Nuvation Bio Class A (NUVB) closed at $3.78 on November 18, 2026, down 3.1% from the previous close, on volume of 5,687,816 shares (30-day average 4,943,487).
Data as of November 18, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 6, 2026 | Calendar Put Spread | 18-Dec-26 : 17-Jun-27 5 P | 600 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 18, 2026. See the largest for 5, 30, 60 and 90 days
TipRanks (Wed, 18-Nov 4:50 AM ET)
Analysts Conflicted on These Healthcare Names: Nuvation Bio (NUVB) and Sana Biotechnology (SANA)
TipRanks (Tue, 17-Nov 7:30 AM ET)
TipRanks (Tue, 17-Nov 7:01 AM ET)
Nuvation’s Safusidenib Shows Durable Benefit, With Key 2027 Readouts Ahead
TipRanks (Mon, 16-Nov 11:55 AM ET)
PRNewswire (Mon, 16-Nov 8:00 AM ET)
Nuvation Bio Earnings Call Highlights IBTROZI Momentum
TipRanks (Sat, 14-Nov 8:43 PM ET)
Brain Cancer Biotech Race Heats Up as NeOnc, Nuvation, Jazz and Cerenome Present New Data at SNO
Globe Newswire (Fri, 13-Nov 1:41 PM ET)
Nuvation Bio to Present at the Jefferies Global Healthcare Conference in London
PRNewswire (Tue, 10-Nov 4:05 PM ET)
Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
PRNewswire (Wed, 4-Nov 4:05 PM ET)
PRNewswire (Mon, 2-Nov 8:00 AM ET)
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
Nuvation Bio Class A trades on the NYSE stock market under the symbol NUVB.
As of November 19, 2026, NUVB stock price climbed to $3.87 with 3,322,700 million shares trading.
NUVB has a beta of 1.20, meaning it tends to be more sensitive to market movements. NUVB has a correlation of 0.04 to the broad based SPY ETF.
NUVB has a market cap of $1.36 billion. This is considered a Small Cap stock.
Last quarter Nuvation Bio Class A reported $45 million in Revenue and -$.12 earnings per share. This beat revenue expectation by $11 million and missed earnings estimates by -$.02.
In the last 3 years, NUVB traded as high as $9.75 and as low as $1.21.
The top ETF exchange traded funds that NUVB belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.
NUVB has underperformed the market in the last year with a price return of -19.4% while the SPY ETF gained +11.6%. NUVB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -44.4% and -18.2%, respectively, while the SPY returned -4.8% and -4.9%, respectively.
NUVB support price is $3.65 and resistance is $3.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NUVB shares will trade within this expected range on the day.